#SFHS2609984AOrder of April 13, 2026, setting the retail price of the magistral preparation of aprepitant covered by health insurance until the availability of the concerned medication
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law sets the price for a specific medicinal preparation made with aprepitant, ensuring it remains covered by health insurance in France until the original medication is available again. It specifically impacts pharmacists and patients needing this treatment since it regulates the cost they will pay. The regulation ends automatically when the national health agency announces that the original medication is back on the market.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Sets a fixed retail price for a magistral preparation of aprepitant.
- Coverage guaranteed by health insurance until the original medication is available.
- Regulation ends automatically upon market availability announcement of the original drug.
Obligations
What this law requires
Set and apply the retail selling price of APREPITANT 320 mg - 16 mL 20 mg/mL oral suspension at exactly €64.65 (TTC), comprised of €57.79 (TTC) manufacturing costs and €6.66 (TTC) dispensing fees
Discontinue application of this pricing order automatically upon publication of the decision by the Director General of the National Agency for the Safety of Medicines and Health Products (ANSM) on their website announcing the resumption of availability of the original aprepitant medication
Ensure health insurance coverage applies to the magistral preparation of aprepitant at the price of €64.65 (TTC) during the period this order is in effect
Monitor the ANSM website for the official decision announcing the end of the shortage recommendation and the return to market of the original aprepitant medication